This study developed a Lupus Disease Activity Immune Index integrating 32 soluble mediators weighted by autoantibody burden, successfully distinguishing active from low disease activity, correlating with SLEDAI scores, and identifying renal involvement to guide objective SLE management.
Read MoreThis study refined a Lupus Disease Activity Immune Index using 12 prioritized soluble mediators and autoantibody breadth, significantly distinguishing low versus active SLE, correlating with hSLEDAI, and identifying renal involvement, supporting objective, treat-to-target disease monitoring in practice
Read MoreThis study refined a blood-based Lupus Disease Activity Immune Index using nine key soluble mediators and autoantibody breadth, accurately distinguishing active from low/quiescent SLE and correlating with hSLEDAI, supporting objective, treat-to-target monitoring in clinical practice.
Read MoreThis study refined a blood-based Lupus Disease Activity Immune Index(L-DAI) using 33 soluble mediators and autoantibody breadth with machine learning, accurately distinguishing active from low SLE activity and offering clinically actionable, objective augmentation to traditional scoring systems
Read MoreThis study assessed the parallel use of L-FRI and L-DAI to assess simultaneous risk of future disease flare and concurrent disease activity to guide therapy. Results showed that combined assessment best identified imminent flares and concurent disease activity, supporting early intervention and clinical trial utility.
Read MoreThis study evaluated the association between both L-DAI and hSLEDAI and patient reported quality of life (HRQol). Higher biomarker-derived disease activity scores correlate with lower patient-reported quality of life, validating L-DAI and hSLEDAI as effective lupus monitoring tools.
Read MoreThis study evaluated L-FRI and L-DAI in parallel to determine the risk of future flare and concurrent disease activity. Simultaneous assessment improves identification of lupus patients with concurrent active disease and imminent flare risk.
Read MoreThis review highlights the need for predictive biomakers in SLE. A soluble mediator score showed high predictivity of impending flare in diverse population, offering a promising tool for early flare detection and intervention
Read More